E N D
1. The Pancreas Aviad Hoffman, MD
Demetrius Pertsemlidis, MD
October 20, 2005
2. History Herophilus, a Greek anatomist and surgeon; one of the founders of the ancient school of Medicine in Alexandria, Egypt.
3. Ruphos, an anatomist - surgeon of Ephesus.
“pancreas” - "all flesh"
Diabetes, named by Aretaeus
Asia Minor,
(ca A.D. 81-150).
5.
1958 –
Frederick Sanger determining the molecular structure of insulin.
6. Anatomy
9. Embryology
11. Normal pancreatic duct
12. Sphincters of the pancreas and bile duct
13. Annular Pancreas
15. Arterial supply of the pancreas
16. Venous drainage of the pancreas
19. Histology of the pancreas 85% exocrine pancreas
2% endocrine pancreas
Regulatory feedback system for digestive enzyme and hormone secretion
Coordinated function
20. The exocrine pancreas
23. Secretin released from duodenual mucosa in response to acidic chyme passing through the pylorus
Major stimulant for HCO3 secretion, buffering gastric acid
Provides optimal environment for pancreatic enzymes
25. Cholecystokinin Released from the jejunum in response to
luminal digestion products of fat and protein
Major stimulant for enzyme secretion
26. Neural regulation of exocrine secretion
27. Regulation of Pancreatic Secretion Neural/Hormonal/Metabolic
29. Pancreatic secretion
Pancreatic juice - 800-1200ml/day
Bicarbonate - 60-120meq/l, pH 7.6-8.2
Basal rate 0.2-0.3ml/min, max – 5ml/min (secretin)
Chloride secretion varies inversely to bicarbonate
Chloride/ Bicarbonate sum is constant
Na+ and K+ isotonic and constant
31. Pancreatic enzymes
34. Familial pancreatitis
Enterokinase
Trypsinogen ? Trypsin
Deficiency of:
pancreatic secretory trypsin inhibitor (PSTI)
SPINK
35. Endocrine pancreas
36. Pancreatic neuroendocrine peptide products Hormones Islet Cell Functions
Insulin ß Decreased gluconeogenesis, glycogenolysis, fatty
acid breakdown and ketogenesis
Increased glycogenesis, protein synthesis
Glucagon a Opposite effects of insulin; increased hepatic
glycogenolysis and gluconeogenesis
Somatostatin d Inhibits gastrointestinal secretion
Inhibits cell growth
Pancreatic PP Inhibits pancreatic exocrine secretion and secretion
polypeptide of insulin
stimulated by Vagus
Facilitates hepatic effect of insulin
Amylin (IAPP) ß Counterregulates insulin secretion and function
Pancreastatin ß Decreases insulin and somatostatin release
Increases glucagon release
Decreases pancreatic exocrine secretion
d -1, EC, G cells Rare
IAPP = islet amyloid polypeptide.
37. Regulation of neuroendocrine secretion Neural/Hormonal/Metabolic
Neural
parasympathetic
sympathetic
Hormonal
insulin/glucagon
somatostatin
GI hormones
Metabolic
glucose
amino acids
fatty acids
42. pancreatitis 300,000 cases/year
10-20% are severe
of them up to 30% mortality rate
3 times higher for blacks than whites
males more often than females
43. ?
44. The Cullen sign is a bluish discoloration around the umbilicus resulting from hemoperitoneum.
Severe necrotizing pancreatitis
45. ?
46. The Grey-Turner sign is a reddish-brown discoloration along the flanks resulting from retroperitoneal blood dissecting along tissue planes
47. Etiology Biliary tract disease (38%)
Alcohol (35%)
Post-ERCP (4%)
Trauma (1.5%)
Hereditary pancreatitis ( <1%)
Hypercalcemia ( <1%)
Hypertriglyceridemia ( <1%)
Tumor ( <1%)
Developmental abnormalities ( <1%)
Pancreas divisum / Annular pancreas
Postoperative ( <1%)
48. Drugs (~1.4%) Diuretics furosemide, hydrochlorothiazide,
Immunosupresant azathioprine,
6-mercaptopurine, corticosteroids
Antibiotics tetracycline, nitrofurantoin, metronidazole, sulfonamides
Anti neoplastic asparaginase, cisplatin, cytosine arabinoside
sulindac, valproic acid, didanosine, methyldopa, estrogens, pentamidine, 5- ASA, octreotide, methandienone, phenformin, piroxicam, procainamide, colaspase, chlorthalidone, cimetidine, diphenoxylate, ethacrynic acid.
49. Infection ( <1%) Viral : mumps, Epstein-Barr,coxsackievirus, echovirus, varicella-zoster, and measles, AIDS (opportunistic infections, neoplasms, drugs)
Bacterial : Mycoplasma pneumoniae, Salmonella, Campylobacter, and Mycobacterium tuberculosis.
Parasites : ascariasis (resulting from the migration of worms in and out of the duodenal papillae).
50. Tityus trinitatis Toxins
51. Autoimmune
Kidney transplant recipients(1.2-6.8%)
Idiopathic (10%)
52. Pathophysiology
Intraductal hypertention
Disruption in the normal separation of
lysosomal and pancreatic enzymes
53. Prognostic indicators Glasgow
Ranson
Balthazar
APACHE-II
54. Cystic neoplasms of the pancreas Serous cystadenoma (32-39%)
Mucinous cystadenoma (10-45%)
Intraductal Papillary Mucinous Neoplasm (11-33%)
Solid-cystic neoplasm (<3-4%)
Cystic neuroendocrine neoplasm (rare)
Ductal adenoca with cystic degeneration (rare)
Acinar-cell cystadenocarcinoma (rare)
55. Diagnosis Serous and mucinous neoplasms:
Mean age 50 yrs
Mostly women
Asymptomatic (< 75%)
Symptoms:
Abdominal pain
Mass
Jaundice
Prior pancreatitis
56. Serous Cystic Neoplasms Most common
Minimal malignant potential (< 10 reports)
Multiple cysts
Polycystic (70%)
Oligocystic
Honeycomb
Central stellate scar/calcification (30%)
57. Mucinous Cystic Neoplasms Majority in body/tail
Thick capsule
No communication w/ duct
58. IPMN Proximal sites
Cystic dilatation of main PD or side branch
Mucin-filled ampulla
59. Cystic Pancreatic Lesions
60. Treatment Serous cystic lesions
Resection only for symptoms, or ambiguity
Enucleation, central pancreatectomy?
Mucinous cystic lesions
All require resection 2nd malignant potential
Operation based on location
IPMN
Surgery indicated
Total pancreatectomy vs. subtotal w/ frozen section margin
61. Results Generally favorable
5 yr survival:
mucinous cystadenoma > 95%
Mucinous ca 17-33%
IPMN > 50%; <30% if invasive
Surveillance?